New Risk • Jul 13
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 8.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.1% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. 공고 • Jun 04
Getinge Launches Vasoview Hemopro 3 Endoscopic Vessel Harvesting System Getinge announced the launch of the Vasoview Hemopro 3 Endoscopic Vessel Harvesting (EVH) System, including the Hemopro 3 Harvesting Tool and dedicated Hemopro 3 Power Supply. The system represents the latest evolution of Getinge's EVH platform, enhancing decades of experience supporting coronary artery bypass grafting (CABG) procedures. Endoscopic vessel harvesting is a minimally invasive technique used to obtain blood vessels, most commonly the saphenous vein or radial artery, for use in CABG surgery. Vessel harvesting plays a critical role in procedural success, as conduit quality and incision-related complications can significantly impact outcomes and recovery. Compared with traditional open harvesting methods, EVH has been associated with reduced wound complications, less postoperative pain, faster recovery, and improved cosmetic results. Getinge has completed an Initial Launch of the Vasoview Hemopro 3 EVH System and has received valuable, positive customer feedback. Getinge has continuously refined EVH technology with a focus on preserving conduit quality while improving the patient and clinician experience. Through close collaboration with vessel harvesting specialists, Getinge has advanced EVH technology in a deliberate, user-driven way, ensuring solutions evolve alongside clinical practice. The Vasoview Hemopro 3 system incorporates targeted enhancements across ergonomics, energy control, visualization, and workflow efficiency, informed by input from more than 100 vessel harvesting specialists worldwide. A redesigned Harvesting Tool features an ergonomic, game-controller-style handle and a soft-touch Activation Toggle that allows activation with minimal force and multiple hand positions, supporting clinician comfort and control throughout the procedure. The system also introduces simplified connectivity through an integrated Harvesting Tool Power Cable, providing a one-click connection to the new Vasoview Hemopro 3 Power Supply and eliminating the need for extension cable sterilization. The dedicated Power Supply is designed to deliver consistent energy and promote efficient cut-and-cautery performance with minimal downtime. Hemopro 3 includes features which support consistent visibility, safety, and workflow efficiency during EVH. Vasoview Hemopro 3 is launching in the U.S., with a training supported rollout available for U.S. customers. Getinge plans a phased expansion outside the U.S., with availability in additional markets to follow based on regulatory approvals and market readiness. Vasoview Hemopro 2 will continue to be available as Getinge rollout availability of Vasoview Hemopro 3. Recent Insider Transactions • May 31
CEO, President & Director recently bought €436k worth of stock On the 29th of May, Mattias Perjos bought around 25k shares on-market at roughly €17.43 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Mattias has been a buyer over the last 12 months, purchasing a net total of €715k worth in shares. Valuation Update With 7 Day Price Move • May 22
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €18.75, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 19x in the Medical Equipment industry in Italy. Total returns to shareholders of 8.3% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €32.79 per share. New Risk • May 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.2% average weekly change).